ResearcherFirst Affiliated Hospital Zhejiang UniversityNo recent work listed
Chenyu W Hu
Matched on ORCID iD 0009-0008-9927-4920; OpenAlex author ID A5020720070. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 10
2017: 1 paper · 2018: 1 paper · 2019: 1 paper
Papers 3
- Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pa… Co-author DOI 10.3389/fonc.2019.01377↗
- Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase. Co-author DOI 10.1021/acs.molpharmaceut.8b00298↗
- MicroRNA Expression Profiling of Pancreatic Cancer Cell Line L3.6p1 Following B7-H4 Knockdown. Co-author DOI 10.1159/000485086↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Hangping Yao · 3 shared papers, 2017–2019 · strength 0.24
- Paper Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Tar… DOI 10.3389/fonc.2019.01377↗
- Paper Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpre… DOI 10.1021/acs.molpharmaceut.8b00298↗
- Paper MicroRNA Expression Profiling of Pancreatic Cancer Cell Line L3.6p1 Following B7-H4 Knockdown. DOI 10.1159/000485086↗
- Ming‐Hai Wang · 2 shared papers, 2018–2019 · strength 0.17
- Paper Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Tar… DOI 10.3389/fonc.2019.01377↗
- Paper Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpre… DOI 10.1021/acs.molpharmaceut.8b00298↗
- Bo Hong · 2 shared papers, 2017–2019 · strength 0.16
- Yun Qian · 2 shared papers, 2017–2019 · strength 0.16
- Xiangming Xu · 1 shared paper, 2019 · strength 0.09
- Linghui Chen · 1 shared paper, 2018 · strength 0.08
- Weilin Wang · 1 shared paper, 2018 · strength 0.08
- Qi Wang · 1 shared paper, 2017 · strength 0.06
- Lingwei Shen · 1 shared paper, 2017 · strength 0.06
- Wenxuan Wu · 1 shared paper, 2017 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.